Patrick Kesslak's Colleagues at Alzheon
Amy-Jayne McCabe
Office Manager and Senior Executive Assistant to Martin Tolar, CEO of Alzheon
Patrick Kesslak's Contact Details
508-861-7709
United States
Alzheon
Patrick Kesslak's Company Details
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer's clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer's patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com